Pediatric Cardiology News

Bromocriptine, a drug previously used to treat adults with type 2 diabetes and Parkinson’s disease, improved BP and central and peripheral aortic stiffness over 4 weeks in adolescents with type 1 diabetes, researchers reported.

Regeneron announced the FDA has accepted for priority review the supplemental biologics license application for evinacumab-dgnb as adjunctive treatment for homozygous familial hypercholesterolemia in children aged 5 to 11 years.

CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be a safe and effective alternative compared with the current standard of care for this age group, researchers reported.

CHICAGO — Survival rates have almost doubled for children who experienced in-hospital cardiac arrest during the last 20 years, with the greatest gains in children who experienced cardiac arrest after cardiac surgery, researchers reported.

Children who experienced adversity from age 0 to 15 years were at elevated risk for developing CVD in young adulthood compared with those who did not, researchers reported in the European Heart Journal.

PHILADELPHIA – In anti-Ro/La-positive pregnancies, most fetal echocardiography screenings for congenital heart block fail to occur by the recommended time, according to data presented at ACR Convergence 2022.

PHILADELPHIA — In children with acute Kawasaki disease where fever symptoms have resolved, continued daily monitoring for 1 to 2 weeks is strongly recommended, according to new guidelines released during ACR Convergence 2022.

CHICAGO — In infants undergoing heart surgery with cardiopulmonary bypass, the use of the steroid methylprednisolone did not reduce odds of a worse outcome compared with placebo, according to the STRESS trial.

Balloon angioplasty and stent implantation procedures in the early postoperative period after congenital heart surgery are overall relatively safe and effective, data from a retrospective, single-center study show.

SAN DIEGO — Adolescents with obesity had a BMI reduction of 16.1% at 68 weeks with once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention, results similar to those seen with adults, according to top-line results presented at ObesityWeek 2022.